However, the medication can cause a slight increase in resting heart rate, which some patients might confuse with blood pressure changes
Abbreviations ACEI: angiotensin-converting enzyme inhibitors AHAs: anti-hyperglycemic agents Ang II: angiotensin II ARBs: angiotensin receptor blockers BP: blood pressure BUN: blood urea nitrogen CI: confidence interval CV: cardiovascular DKD: diabetic kidney disease DPP-4: dipeptidyl peptidase-4 eGFR: estimated glomerular filtration rate EGP: endogenous glucose production FPG: fasting plasma glucose GFR: glomerular filtration rate GLP-1: glucagon-like peptide-1 GLP1-RAs: glucagon-like peptide-1 receptor agonists HbA1c: glycated haemoglobin HDL-C: high density lipoprotein-cholesterol HF: heart failure HGP: hepatic glucose production LDL-C: low density lipoprotein-cholesterol MACE: major adverse cardiovascular events MRAs: mineralocorticoid receptor antagonists NF-kB: nuclear factor kappa B OLETF: Otsuka Long-Evans Tokushima Fatty PK-PD: pharmokinetics and pharmacodynamic RAAS: reninangiotensinaldosterone system RAS: reninangiotensin system RCT: randomized controlled trial SBP: systolic blood pressure SGLT2: sodiumglucose co-transporter 2 STZ: streptozocin T2DM: type 2 diabetes mellitus UACR: urine albumincreatinine ratio UGE: urinary glucose excretion References Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al
Trends in Endocrinology & Metabolism, 35 (1), 7483
However, there is currently a Multidistrict Litigation case centralized in the Eastern District of Pennsylvania
FOXO4-DRI targets a biological process (senescent cell clearance) that produces gradual, systemic effects rather than immediate, obvious changes
These changes tend to be associated with normal signs of aging like poor wound healing, thinning of the skin, and no tissue regeneration
